Abstract Lysophospholipids (LysoPLs) are bioactive lipid species involved in cellular signaling processes and the regulation of cell membrane structure. LysoPLs are metabolized through the action of lysophospholipase A1 (LYPLA1) and lysophospholipase A2 (LYPLA2). A new X-ray crystal structure of LYPLA2 compared with a previously published structure of LYPLA1 demonstrated near-identical folding of the two enzymes; however, LYPLA1 and LYPLA2 have displayed distinct substrate specificities in recombinant enzyme assays. To determine how these in vitro substrate preferences translate into a relevant cellular setting and better understand the enzymes’ role in LysoPL metabolism, CRISPR-Cas9 technology was utilized to generate stable KOs of Lypla1 and/or Lypla2 in Neuro2a cells. Using these cellular models in combination with a targeted lipidomics approach, LysoPL levels were quantified and compared between cell lines to determine the effect of losing lysophospholipase activity on lipid metabolism. This work suggests that LYPLA1 and LYPLA2 are each able to account for the loss of the other to maintain lipid homeostasis in cells; however, when both are deleted, LysoPL levels are dramatically increased, causing phenotypic and morphological changes to the cells. —Wepy, J. A., James J. Galligan, P. J. Kingsley, S. Xu, M. C. Goodman, K. A. Tallman, C. A. Rouzer, and L. J. Marnett. Lysophospholipases cooperate to mediate lipid homeostasis and lysophospholipid signaling. *J. Lipid Res.* 2019. 60: 360–374. 

Lysophospholipids (LysoPLs) are detergent-like lipid species that play a critical role in a wide variety of cellular signaling mechanisms in addition to maintaining the structure, shape, and fluidity of cell membranes (1–3). Each LysoPL comprises one nonpolar acyl chain, varying in length and degree of unsaturation, and a polar glycerophosphate headgroup. Based on the structure of the headgroup, LysoPLs belong primarily to one of six classes, including lysophosphatidic acids (LPAs), lysophosphatidylincholines (LPCs), lysophosphatidylethanolamines (LPEs), lysophosphatidylglycerols (LPGs), lysophosphatidilynositol (LPIs), and lysophosphatidylerines (LPSs), each with distinct biological functions dependent on physiological location and availability of their respective cellular receptors.

LysoPLs have been shown to elicit a wide range of biological effects, including cell proliferation, intracellular calcium mobilization, metabolic activity, inflammatory and antiinflammatory processes, and neuritogenesis (4–20). These effects are generally evoked through ligand-receptor interactions, but this is not always the case. For example, high physiological concentrations of LPCs (≥200 µM in human plasma) call into question a receptor agonist role in some circumstances, and accruing evidence supports the hypothesis that they can elicit effects by altering membrane properties or interacting directly with proteins in ways other than saturable binding to a specific site (21–24). For example, LPCs have been shown to directly promote Ras-mediated activation of the MAPK signaling pathway by a mechanism that does not involve characterized LysoPL receptors (17). In contrast, LPEs, LPGs, and LPIs have also been shown to activate this signaling pathway, but they...
Lysophospholipases (LysoPLs) play a significant role in modulating the phosphorylation state of the Ras/Raf/MEK (MAPK/ERK kinase)/ERK cascade (16, 18, 25–27). This signaling pathway is critical for the regulation of cell-cycle progression and differentiation (28–31). Indeed, LysoPL-mediated activation of the MAPK signaling pathway has consistently been shown to induce neuronal differentiation in neuroblastoma cells (16–19).

As LysoPLs are potent signaling molecules, their cellular levels are carefully regulated through three primary enzymatic pathways: lysophospholipase-mediated hydrolysis, acyltransferase-mediated generation of phospholipids (PLs), and transacylase-mediated generation of PLs. In mammalian cells, the lysophospholipase pathway predominates (32–38). Lysophospholipase A1 (LYPLA1) and lysophospholipase A2 (LYPLA2) are cytosolic serine hydrolases with esterase and thioesterase activity that are partially responsible for the metabolism of LysoPLs. LYPLAs hydrolyze LysoPLs at the sn-1 and, to a lesser extent, sn-2 positions to yield a FFA and a derivatized glycerophosphate that can then be recycled by a variety of phospholipases and acyltransferases to restructure the composition of the lipid membrane in a process called the Lands cycle (Scheme 1) (39–42). Inhibition of these regulatory mechanisms and the associated changes in LysoPL homeostasis have been associated with a variety of neurological diseases, including cerebral atherosclerosis, vascular dementia, and Alzheimer’s disease (24, 43–47).

In addition to their role in the degradation of LysoPLs, LYPLAs display other activities. For example, the monoacylglycerol and endocannabinoid, 2-arachidonoylglycerol, is oxygenated by cyclooxygenase-2 to generate prostaglandin glycerol esters (PG-Gs) (48, 49). Our previous work has identified LYPLA2 as a PG-G hydrolase, converting PG-Gs to free prostaglandins (PGs) (41). This suggests a role for LYPLA2 in endocannabinoid metabolism. Furthermore, LYPLA1 and LYPLA2 are among a small pool of enzymes known to exhibit thioesterase activity on palmitoylated proteins such as the Gαq subunit of heterotrimeric G proteins and Ras (50, 52). This posttranslational modification serves to alter protein conformation and/or tether a cytosolic protein to a lipid membrane with the addition of a lipophilic acyl moiety covalently bound to cysteine residues via a thioester linkage (53–56). LYPLA1 and LYPLA2 act to remove these acyl modifications as part of a dynamic palmitoylation process, regulating the subcellular location and conformation of a variety of cellular proteins (50, 52, 54, 57).

Despite relatively high sequence homology (68% identical, 83% similar), LYPLA1 and LYPLA2 display moderate substrate specificity in regard to LysoPL hydrolysis (32, 58–60). For example, whereas LYPLA1 displays general promiscuity in regard to the different LysoPL classes, LYPLA2 is considered more specific, preferring LPCs and LPEs. However, most of this work has been done with recombinant enzymes and exogenous substrate, despite the fact that substrate specificity of serine hydrolases differs between in vitro and cellular settings, where subcellular location, competitive metabolism, and protein expression levels impact relevant substrate availability (61).

To understand the substrate specificity of LYPLA1 and LYPLA2 in cells, we have utilized a murine Neuro2a neuroblastoma model, in which LYPLA activity is relatively high and commonly studied (62, 63). Using CRISPR-Cas9 technology, we have generated Neuro2a KO cell lines lacking Lypla1, Lypla2, or both genes to quantify and compare endogenous LysoPL levels in the absence of respective lysophospholipase activity. This approach offers a physiologically relevant model to determine the roles of LYPLA1 and LYPLA2 in LysoPL hydrolysis, as well as the consequences of the loss of their activity. Our results demonstrate that the roles played by the two enzymes in intact cells are not necessarily reflected by the results obtained with purified protein preparations.

MATERIALS AND METHODS

Chemicals, reagents, and statistics

All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise stated. PG-Gs and deuterated PGs (PGE2-d4)
were purchased from Cayman Chemicals (Ann Arbor, MI). All LysoPLs were purchased from Avanti Polar Lipids (Alabaster, AL). LC/MS solvents were from Fisher (Pittsburgh, PA). The 16:0-d\(_4\) LPC was synthesized as described in supplemental data. Recombinant enzyme was expressed and purified as described previously, using cDNA from OriGene Technologies (Rockville, MD) (41). HIS-Select nickel affinity beads were from Sigma-Aldrich. HiPrep 16/60 Sephacryl S-200 HR was from GE Healthcare (Little Chalfont, UK). Neuro2a cells were obtained from the American Type Culture Collection (Manassas, VA). Cell culture reagents were purchased from Invitrogen (Grand Island, NY). All experiments were performed twice in triplicate, unless otherwise noted, and statistical significance was determined using one-way ANOVA, unless otherwise noted.

**Cell culture**

Neuro2a cells were maintained as adherent cultures in DMEM supplemented with 10% FBS from Atlas Biologicals (Fort Collins, CO). Cells were cultured at 37°C and 5% CO\(_2\), grown to no more than 75% confluency, and trypsinized to passage.

**X-ray crystallography**

Recombinant human LYPLA2 (10 mg/ml) was preincubated with PMSF (10× molar ratio). Crystals were prepared by hanging-drop vapor diffusion with drops containing 2 µl of enzyme-inhibitor complex and 2 µl of reservoir solution containing 0.1 M sodium citrate (pH 5.6) and 15–30% polyethylene glycol 3350. After 1–2 weeks, irregular crystals formed and were supplemented with 25% glycol for cryopreservation. Diffraction data for LYPLA2-PMSF were collected on the Advanced Photon Source LS-CAT beamline 24-ID-E at 100 K. The data were processed with X-ray diffraction spectroscopy and solved to 2.70 Å resolution by molecular replacement using Phaser with the A chain of LYPLA1 [Protein Data Bank (PDB) accession no. 1FJ2] as the search model. Two monomers were present in one asymmetric unit. Difference electron density maps contoured at 3.0 σ showed the presence of a phenylmethylsulfonyl moiety associated with active Ser122. Data collection and refinement statistics for each structure are listed in supplemental Table S1. Figures were generated using PyMol Molecular Graphics system (Schrödinger). Atomic coordinates for LYPLA2-PMSF have been deposited in the PDB (accession no. 6BJE).

**Recombinant LYPLA activity assays**

Recombinant enzyme solutions (100 nM) were prepared in PBS with or without 0.5% (w/v) FA-free BSA, and 100 µl aliquots of each solution were preincubated at 37°C for 5 min. PGE\(_2\)-G, 16:0-d\(_3\) LPC, or a mix of sn1- and sn2-18:0 LPC (1.5 nmol) was added in 1 µl ethanol, and samples were vortexed and then incubated at 37°C for 10 min. For quantitation of product formation (PGE\(_2\)-G and 16:0-d\(_3\) LPC), enzymatic activity was quenched by adding 1 ml of ice-cold ethyl acetate with 0.5% (v/v) acetic acid containing either 20 ng PGE\(_2\)-G or 1 nmol 16:0-d\(_3\), as internal standards. Samples were vortexed, and the organic layers were collected and dried under nitrogen. To quantify PG-G hydrolysis, extracts were resuspended in 200 µl acetonitrile and analyzed via LC/ESI/MS/MS, as described below. To quantify 16:0-d\(_3\) LPC hydrolysis, samples were derivatized with pentafluorobenzyl (PFB) bromide based on a previously described method with minor adaptations (64). Specifically, extracts were reconstituted in 150 µl acetonitrile, and then 200 µl of 100 nM tetrabutylammonium hydrogen sulfate in 100 nM dibasic sodium phosphate buffer was added. Following addition of 200 µl 2% (v/v) PFB bromide in chloroform, the samples were vortexed and sonicated for 45 min at 35% output using a Virsonic Cell Disrupter (model 16-850), and then lipids were extracted via the addition of 1 ml of 9:1 hexanes:ethanol. The organic layer was removed, dried under nitrogen, and resuspended in 200 µl acetonitrile for analysis via LC/atmospheric-pressure chemical ionization (APCI)/MS/MS, as described below. For quantitation of substrate remaining (18:0 LPC), enzymatic activity was quenched by adding 100 µl of ice-cold ethanol with 0.5% (v/v) acetic acid containing 2 µM 17:0 LPC as an internal standard. Samples were immediately analyzed via LC/ESI/MS/MS, as described below, to prevent the equilibration of sn1-18:0 and sn2-18:0 LPC isomers via acyl migration.

**Generation and validation of LYPLA KO cells using CRISPR-Cas9**

CRISPR technology was utilized to generate genetic LO cells as described by Ran et al. (65). gRNAs were designed to target early exons of the LYPLA1 and LYPLA2 genes. gRNA oligomers (LYPLA1 gRNA: TTCCAGTGCCCCGGCCTGG; LYPLA2 gRNA: AGCT-AGGCGGAAACGGCGG) were annealed, phosphorylated, and ligated into digested pspCas9(BB)-2A-puro plasmid (plasmid no. 62988, Addgene, Cambridge, MA). Neuro2a cells (1.5 × 10\(^7\)) were suspended in 2 ml of DMEM supplemented with 10% FBS and plated in 6-well plates. The following day, 5 µg of each plasmid was combined with 10 µl Lipofectamine 2000 reagent (Invitrogen) in 1 ml Opti-MEM and incubated at room temperature for 30 min. Neuro2a culture medium was replaced with the appropriate plasmid- lipofectamine solution, and cells were incubated at 37°C for 24 h. The medium was then replaced with fresh DMEM plus 10% FBS, and cells were allowed to recover for 24 h at 37°C prior to the addition of 0.75 µg/ml puromycin. Cells were incubated at 37°C for 48 h before replacing the medium. After recovering for ~1–2 weeks, cells were pelleted, resuspended in sorting buffer (PBS + 4% FBS), and strained to separate clumps of cells. Solutions were sorted by flow cytometry using a 5-laser BD LSRII with a 100 µm nozzle at the Vanderbilt Medical Center Flow Cytometry Core to isolate single cell cultures in 96-well plates for each cell line. Clones were incubated until they reached ~70% confluency and then passaged until enough cells could be harvested for KO validation via Western blotting. Cells lacking both Lypla1 and Lypla2 genes, or double-KO (DKO) cells, were generated by repeating this process to target the Lypla1 gene in the Lypla2\(^{−/−}\) cells.

**Western blot analysis**

Protein expression was determined by Western blot analysis as previously described (41, 66). Samples were separated by SDS-PAGE. Then, proteins were transferred to a nitrocellulose membrane and blocked with Odyssey Blocking Buffer (LI-COR, Lincoln, NE) for 1 h at room temperature and probed with rabbit anti-LYPLA1 (1:1,000 v/v, abcam, Cambridge, UK), rabbit anti-LYPLA2 (1:1,000 v/v, Vanderbilt Antibody and Protein Resource Core; polyclonal rabbit anti-LYPLA2 antibody was generated by the Vanderbilt Antibody and Protein Resource Core and can be obtained through contact with corresponding author, L. J. Marnett.), rabbit anti-ERK1/2 (1:1,000 v/v, Cell Signaling Technologies (CST), Danvers, MA), rabbit anti-phospho-ERK1/2 (1:1,000 v/v, CST), rabbit anti-MEK1/2 (1:1,000 v/v, CST), rabbit anti-phospho-MEK1/2 (1:1,000 v/v, CST), or goat anti-β-actin (1:5,000 v/v, Santa Cruz Biotechnologies, Santa Cruz, CA) overnight at 4°C. Membranes were washed and incubated with IR-visible anti-rabbit or anti-goat secondary Abs (1:5,000 v/v, LI-COR). Blots were visualized using an Odyssey IR Imager.

**Assay for LYPLA activity in cell lysates**

WT, Lypla1\(^{−/−}\), Lypla2\(^{−/−}\), or DKO cells (1 × 10\(^6\)) were plated in 8 ml DMEM with 10% FBS in 100 mm plates and incubated at 37°C for 24 h prior to harvesting. Cell pellets were suspended in a buffer containing 25 mM Tris (pH 7.5), 0.1 mM EDTA, and 0.1 mM DTT. Cells were sonicated into solution via 10 × 1 s pulses
at 35% output. Debris was pelleted via centrifugation at 15,000 g for 10 min, and soluble protein concentration in the supernatant was determined via Pierce™ BCA protein assay (Thermo Scientific, Rockford, IL). Solutions (250 µg/ml) of each enzyme were prepared, and 100 µl aliquots were preincubated at 37°C for 5 min. PGE₂-G or 16:0-d₃ LPC (1.5 nmol) was added in 1 µl ethanol, and samples were vortexed and incubated at 37°C for 1 h. Enzymatic activity was quenched by adding 1 ml of ice-cold ethyl acetate with 0.5% (v/v) acetic acid containing either 20 ng PGE₂-d₃ or 1 nmol 16:0-d₃ as internal standards. Samples were vortexed, and organic layers were collected and dried under nitrogen. FAs were derivatized as described above, and LC/MS/MS analysis was then performed as described below.

**LysoPL extraction**

WT, Lypla1⁻/⁻, Lypla2⁻/⁻, or DKO cells (1 × 10⁶) were plated in 8 ml DMEM with 10% FBS in 100 mm plates and incubated at 37°C for 24 h. Cells were then scraped into 3 ml ice-cold PBS and pelleted. LysoPLs were extracted from cell pellets using a method adapted from Zhao and Xu (67), by resuspending in 200 µl of ice-cold methanol containing 50 nM 17:0 LPA, 250 nM 17:0 LPC, 50 nM 17:1 LPE, 50 nM 17:1 LPS, 50 nM 17:1 LPG, and 150 nM 17:1 LPS. Cells were sonicated with 10 × 10 s pulses at 35% output, and protein was pelleted. Methanol extracts were collected for lipid analyses via LC/ESI/MS/MS as described below. Protein pellets were resuspended in 1 ml PBS containing 0.2% SDS, sonicated with 10 × 10 s pulses at 35% output, and subjected to BCA assay to quantify input protein.

**LC/MS/MS analysis**

For activity assays, samples were run on an LC/MS system consisting of a Shimadzu liquid chromatograph in line with a SCIEX 3200 QTrap mass spectrometer. Analyst software (version 1.6.2) was used for instrument control, data acquisition, and data processing. Quantitation was achieved via stable isotope dilution against the indicated internal standard of PGE₂-d₁ or 16:0-d₂. For PGE₂ analysis, reconstituted samples were run in negative mode on a system configured as described in supplemental Table S2A, B. For 16:0-d₂ analysis, reconstituted samples were run in negative mode on a system configured as described in supplemental Table S3A, B. The Luna liquid chromatography reverse-phase C18 columns were from Phenomenex (Torrance, CA).

For lipidomics experiments, samples were run on an LC/MS system consisting of a Shimadzu liquid chromatograph in line with a SCIEX 3200 QTrap or a SCIEX 6500 QTrap mass spectrometer based on methods described by Okudaira et al. (68) and Aaltonen et al. (69). This method isolates LysoPLs from other glycerolipid and glycerophospholipid species. Analyst software (version 1.6.2) was used for instrument control, data acquisition, and data processing. Quantitation was achieved via internal standard dilution against the respective unnatural 17:0 or 17:1 LysoPL standards of LYPLA1 and LYPLA2 suggest the proteins form weak dimers, size-exclusion chromatography indicates that both enzymes are active as monomers (data not shown).

**RESULTS**

**LYPLA1 and LYPLA2 display high structural alignment**

The crystal structure of apo-LYPLA1 (PDB accession no. 1FJ2) suggests that the enzyme is unusual in that it lacks the traditional cap domain found in other members of the α/β-hydrolase superfamily (75). Instead, the β₄-α₂ loops are positioned as a flexible lid covering the active-site serine, creating a potential hydrophobic channel for lipid binding. Another crystal structure of LYPLA1 (PDB accession no. 5SYM) and the structure of LYPLA2 (PDB accession no. 5SYN) have recently been solved with the specific inhibitors, ML348 and ML349, respectively, bound in their active sites (76). Although the previously reported structures of LYPLA1 and LYPLA2 suggest the proteins form weak dimers, size-exclusion chromatography indicates that both enzymes are active as monomers (data not shown).

We used sparse matrix screening of crystallization to obtain the crystals that were used to solve the structure of LYPLA2 covalently modified by the general serine hydrolase inhibitor, PMSF, at 2.7 Å resolution (PDB accession no. 6BGE) (Fig. 1, supplemental Table S1). This is the second structure of LYPLA2 to be reported, and the first with a covalent modification of the active site Ser122. Consistent with the previously reported structure, LYPLA2-PMSF crystallized as a dimer, although it is equally active in monomer and dimer conformations. Crystals of apo-LYPLA2 were also obtained but failed to diffract for structure studies due to lattice defects. The data confirm that, like LYPLA1, LYPLA2 lacks a cap domain, which is replaced by the β₄-α₂ loops (highlighted in blue in Fig. 1) that act as a flexible lid
near the active site. The LYPLA2-PMSF structure is very similar to that of LYPLA2-ML349; however, small differences in conformation are noted. For example, the $\beta_5\alpha_2$ loop in the two structures is present in distinct conformations (supplemental Fig. S1), with the LYPLA2-ML349 loop extended slightly further than that of LYPLA2-PMSF. This suggests that the loop is able to move to accommodate substrates or inhibitors binding in the channel adjacent to the active Ser122. Additionally, the modified Ser122-PMSF demonstrates a slight shift in position compared with the unmodified Ser122 of the LYPLA2-ML349 structure, likely due to the steric bulk of the PMSF modification.

Consistent with the relatively high sequence homology of LYPLA1 and LYPLA2 (Fig. 2A), a least-squares comparison of their coordinates reveals that the two proteins are folded in nearly identical conformations (Fig. 2B). Superposition across all 215 aligned residues yielded a root-meansquare deviation (RMSD) of 0.878 Å and a quality of alignment (Q-score) of 0.838, suggesting that the protein structures differ by no more than 1 Å (77). This high degree of sequence and structural similarity suggests that the two proteins may share significant overlap in substrate specificity and hydrolytic activity.

**LYPLA1 is a PG-G hydrolase in vitro**

A recent report from our laboratory identified LYPLA2 as the major PG-G hydrolase in cancer cells. At that time, LYPLA1 was ruled out on the basis of siRNA knockdown in cells, but the enzyme’s PG-G hydrolytic activity was not evaluated directly in vitro with purified recombinant protein (41). Therefore, we quantified both LYPLA1 and LYPLA2 activity toward a representative PG-G substrate, PGE$_2$-G. Additionally, as both LYPLA1 and LYPLA2 have been shown to robustly hydrolyze 16:0-LPC, we quantified hydrolytic activity toward the 16:0-LPC species as a representative LysoPL substrate. However, as the product of LysoPL hydrolysis by LYPLAs is a glycerophosphate headgroup (too small and polar for LC separation) and a FA [notoriously omnipresent in solvents, plastics, and glassware, as well as difficult to ionize and fragment (78–80)] (Fig. 3A), we utilized an isotopically labeled 16:0-d$_3$ LPC species and a PFB-Br derivatization for these assays (64). The derivatization yields a PFB-esterified acyl chain, which has electron-capturing properties to enable sensitive ionization and detection in APCI/MS/MS. This method allowed for the LC/MS/MS-based quantification of a FA species by avoiding contamination and ionization issues.

As demonstrated in Fig. 3B, both enzymes were able to hydrolyze these substrates. LYPLA1 hydrolyzed PGE$_2$-G at a rate of 48.1 ± 0.5 µmol/min/mg compared with 93.3 ± 4.7 µmol/min/mg for LYPLA2, and LYPLA1 hydrolyzed 16:0-d$_3$ LPC at a rate of 127 ± 8 µmol/min/mg compared with 129 ± 9 µmol/min/mg for LYPLA2. Thus, contrary to our findings in intact cancer cells, recombinant LYPLA1 displayed substantial PG-G hydrolytic activity. However, whereas the two enzymes hydrolyzed 16:0-d$_3$ LPC with equivalent specific activity, LYPLA2 was significantly more active than LYPLA1 toward PGE$_2$-G. It has been reported that BSA is able to improve hydrolysis of lipid substrates in recombinant serine hydrolase activity assays, presumably by acting as a lipid carrier to better mimic the conditions of a cellular setting, and we have recently shown that the presence of BSA has a significant effect on LYPLA2-mediated PG-G hydrolysis (41, 81). Therefore, we also added BSA to the enzyme solutions to promote substrate availability and compared enzymatic activity toward both PG-G and LysoPL substrates. In the presence of BSA, LYPLA1 hydrolyzed PGE$_2$-G at a rate of 64.2 ± 1.7 µmol/min/mg compared with 170 ± 8 µmol/min/mg for LYPLA2, and LYPLA1 hydrolyzed 16:0-d$_3$ LPC at a rate of 137 ± 14 µmol/min/mg compared with 137 ± 2 µmol/min/mg for LYPLA2. These
results suggest that the addition of BSA promotes the hydrolytic activity of LYPLA2 but not LYPLA1 toward PG-Gs, without significantly affecting the activity of either enzyme toward LysoPLs.

Preliminary studies by our lab have suggested that LYPLA2 prefers the sn1-isomer of PG-G and glycerolipids (41). To determine substrate specificity of LYPLAs toward sn1- versus sn2-isomers of LysoPLs, equilibrium mixtures of sn1-18:0 LPC (∼80%) and sn2-18:0 LPC (∼20%) were added to 100 nM enzyme solutions of LYPLA1, LYPLA2, or a no enzyme control under conditions in which hydrolysis occurred faster than isomeric equilibration. The isomeric composition of the remaining 18:0 LPC substrate was assessed immediately after quenching with acidified ethanol to prevent acyl migration, and PBS controls were included to ensure that changes to isomeric composition were not merely a result of isomeric equilibration. The isomeric composition of the remaining 18:0 LPC substrate was assessed immediately after quenching with acidified ethanol to prevent acyl migration, and PBS controls were included to ensure that changes to isomeric composition were not merely a result of isomeric equilibration. With both LYPLA1 and LYPLA2, only sn1-18:0 LPC isomer levels were significantly decreased after 10 min compared with those in the PBS controls (Fig. 3C). These data demonstrate the specificity of LYPLAs toward sn1-LysoPLs, which is consistent with our published activity of LYPLA2 toward 1(3)-PG-Gs and 1(3)-arachidonoylglycerol.

KO of Lypla genes results in decreased hydrolytic activity

As our results suggested that in vitro enzymatic activity does not necessarily reflect the metabolic contribution of that enzyme in vivo, we sought to better understand the role of LYPLA1 and LYPLA2 in LysoPL turnover in intact cells. CRISPR-Cas9 technology was utilized to generate stable genetic KOs of Lypla1, Lypla2, or both genes in murine Neuro2a neuroblastoma cells. Sanger sequencing was used to verify genetic editing at sites in the Lypla genes targeted by respective gRNAs and overexpressed Cas9 protein. Genetic KOs were validated at the protein level using Western blotting with Abs directed toward LYPLA1 and LYPLA2 (Fig. 4A). Notably, the level of each LYPLA was unaffected by KO of the other isoform. The ability of the cell lines to hydrolyze the canonical PG-G and LysoPL substrates of the LYPLAs was tested using cellular lysates and the previously described hydrolytic activity assays. In addition to avoiding palmitic acid contamination from plastics and solvents, the use of isotopically labeled 16:0-d3 LPC in this assay was instrumental to avoid mistaking the endogenous palmitic acid present in cells for hydrolyzed product of the exogenous substrate. This same problem did not arise in the case of PG-G hydrolysis, as Neuro2a cells lack the cyclooxygenase activity required to generate endogenous PG-Gs or PGs. Enzymatic activity of Neuro2a lysates that had been normalized for protein concentration was quantified as the percent of each substrate hydrolyzed as described in Fig. 3A. The percentages of PGE2-G hydrolyzed in WT, Lypla1−/−, Lypla2−/−, and DKO cell lysates were 50.4 ± 1.3%, 51.3 ± 0.9%, 43.0 ± 0.6%, and 32.1 ± 0.4%, respectively, whereas the percentages of 16:0-d_3 LPC hydrolyzed in WT, Lypla1−/−, Lypla2−/−, and DKO cell lysates were 24.2 ± 3.3%, 23.4 ± 3.5%, 18.8 ± 0.7%, and 11.2 ± 0.3%, respectively (Fig. 4B). Similar to what we observed in our previous work using human cancer cell lines, Lypla1−/− cells exhibited the same PG-G hydrolytic activity as WT cells, whereas the activity in Lypla2−/− cells was significantly lower than that of WT cells. In DKO cells, PG-G hydrolysis was further decreased, suggesting that both enzymes contribute to PG-G hydrolysis and that LYPLA2 can better compensate.
for loss of LYPLA1 than vice versa. This same trend is observed with LysoPL hydrolysis. Notably, however, DKO cells retained 64% and 46% of the PGE2-G and 16:0-d3 LPC hydrolytic activity of WT cells, respectively, indicating that other enzymes are available to catalyze both reactions. It is not possible to know whether expression of these enzymes increases to compensate for the loss of LYPLA1 and/or LYPLA2 in the KO cells. If so, these results would underes-

**LysoPL species are increased in DKO cells**

With the decreased hydrolytic activity observed in the Lypla KO cells, we hypothesized that basal levels of LYPLA substrates would be consequentially increased. To test this hypothesis, we utilized an LC/MS/MS-based targeted lipidomics approach to quantify LPA, LPC, LPE, LPG, LPI, and LPS substrates containing the following acyl moieties at both the sn-1 and sn-2 positions of the glyceryl backbone: 16:0, 16:1, 18:0, 18:1, 18:2, 18:3, 20:4, 20:5, and 22:6. Absolute quantification of each lipid species was normalized to the amount of protein in each sample. As the variance of the LysoPL species was unequal between samples, and values in each sample were not normally distributed, one-way ANOVA could not be used to determine statistical significance. Instead, samples with normal distributions (skewness between $-1$ and 1) were analyzed by Welch’s $t$-test, and samples with abnormal distributions (skewness less than $-1$ or greater than 1) were analyzed by the Wilcoxon rank-sum test. Statistically significant differences in LysoPL levels in Lypla1$^{-/-}$, Lypla2$^{-/-}$, or DKO cells were compared individually to those of WT cells. Results for every identified LysoPL species are listed in Table 1, with values that are significantly different from those of WT cells marked by boldface text. Additionally, these values are displayed in Fig. 5A–F as absolute quantities and in Fig. 5G–L as fold changes normalized to the LysoPL levels in WT cells (with WT values set to 1, represented by dotted lines).

As expected, LPCs were the most abundant of the LysoPL classes, with more prevalent species found in quantities near 500 pmol/mg protein. LysoPLs containing saturated acyl chains of 16 and 18 carbons were generally found at levels much higher than those containing longer or more unsaturated acyl chains. Whereas the LysoPL concentrations of Lypla1$^{-/-}$ cells were mostly comparable to those of WT cells with the exception of 20:4 LPA (1.6-fold
Table 1. Basal LysoPL levels (pmol/mg protein) in WT, Lypla1−/−, Lypla2−/−, and DKO cells, presented as mean (SD)

| Lipid species | Cell line | WT | Lypla1−/− | Lypla2−/− | DKO |
|---------------|-----------|----|-----------|-----------|-----|
| LPA 16:0      | 6.90 (3.15) | 6.95 (1.82) | 9.28 (1.84) | 16.2 (6.23) |
| 18:0          | 3.23 (0.74) | 4.23 (1.05) | 3.31 (0.53) | 4.55 (1.18) |
| 18:1          | 3.54 (0.92) | 3.24 (0.96) | 5.85 (2.84) | 16.3 (14.0) |
| 18:2          | 4.35 (1.49) | 4.85 (0.78) | 6.08 (2.02) | 8.97 (6.54) |
| 18:3          | 0.86 (0.11) | 1.38 (0.24) | 1.02 (0.34) | 1.36 (0.29) |
| LPC 16:0      | 5.45 (86.6) | 509 (41.8) | 823 (77.1) | 1890 (713) |
| 18:0          | 62.9 (8.52) | 62.5 (6.70) | 85.0 (6.32) | 245 (101) |
| 18:1          | 464 (85.9)  | 442 (48.6) | 549 (48.9) | 1410 (527) |
| 18:2          | 416 (98.5)  | 460 (34.4) | 498 (58.0) | 1220 (503) |
| 18:3          | 25.1 (4.48) | 26.8 (1.86) | 38.6 (2.63) | 154 (66.4) |
| LPE 16:0      | 1.01 (0.30) | 1.59 (0.12) | 2.91 (0.27) | 9.81 (2.16) |
| 18:0          | 41.4 (10.1) | 53.5 (6.34) | 51.4 (13.3) | 255 (167) |
| 18:1          | 1.76 (0.46) | 2.14 (0.76) | 3.88 (0.61) | 16.4 (7.96) |
| 18:2          | 22.6 (3.65) | 23.7 (3.19) | 24.8 (6.19) | 101 (61.5) |
| LPI 16:0      | 30.4 (8.19) | 25.7 (6.79) | 35.8 (10.5) | 119 (74.3) |
| 18:0          | 91.0 (44.0) | 70.2 (24.6) | 93.0 (40.4) | 299 (215) |
| 18:1          | 63.3 (15.3) | 53.9 (12.3) | 50.0 (13.2) | 155 (106) |
| 18:2          | 423 (1.78)  | 3.42 (0.99) | 3.10 (1.51) | 12.3 (9.95) |
| 18:3          | 25.2 (13.4) | 26.8 (11.2) | 21.1 (12.5) | 94.5 (88.9) |
| LPG 16:0      | 5.94 (0.38) | 3.99 (0.36) | 6.00 (0.66) | 13.8 (2.93) |
| 18:0          | 41.8 (1.21) | 3.01 (0.37) | 5.08 (0.63) | 11.0 (2.42) |
| 18:1          | 50.5 (2.44) | 31.9 (4.00) | 29.0 (4.40) | 50.5 (14.4) |
| 18:2          | 0.24 (0.01) | 0.32 (0.08) | 0.23 (0.01) | 0.37 (0.01) |
| LPS 16:0      | 15.4 (2.63) | 10.8 (3.26) | 34.2 (6.33) | 86.1 (33.3) |
| 18:0          | 169 (44.2)  | 166 (119)  | 234 (82.1)  | 572 (242) |
| 18:1          | 96.7 (19.8) | 88.6 (21.9) | 139 (15.6)  | 255 (101) |
| 18:2          | 3.60 (0.43) | 2.57 (0.44) | 3.34 (0.71) | 8.63 (4.27) |
| 18:3          | 9.07 (3.27) | 11.1 (2.57) | 10.5 (2.43) | 31.2 (22.9) |
| 18:4          | 5.80 (0.76) | 5.65 (0.93) | 5.52 (0.44) | 11.5 (3.73) |
| 18:5          | 34.7 (5.69) | 29.9 (4.60) | 34.4 (8.78) | 80.0 (43.7) |
| 18:6          | 15.3 (1.65) | 19.4 (5.31) | 26.3 (6.35) | 91.0 (72.9) |
| 18:7          | 0.62 (0.03) | 0.61 (0.06) | 0.60 (0.08) | 1.05 (0.13) |

Boldface values indicate P < 0.05, determined by Welch’s t-test or the Wilcoxon rank-sum test for samples with normal or abnormal distributions, respectively. 

increase) and 20:4 LPC (1.3-fold increase), Lypla2−/− cells displayed some significant differences from WT cells in certain LysoPL species, such as 16:0 LPC (1.5-fold increase), 18:2 LPC (1.5-fold increase), 18:3 LPC (1.8-fold increase), 16:0 LPI (2.2-fold increase), and 18:0 LPI (1.5-fold increase). However, any differences in the single-KO cells were overshadowed by the much greater increases in the levels of many LysoPLs in the DKO cells. This is especially notable with the LPCs, LPEs, LPIs, and LPSs, of which most lipid species increased by 3- to 9-fold in the DKO relative to the WT cells. These results are consistent with the lysophospholipase activity measured in cell lysates (Fig. 4B). Notably, although these large changes in LysoPLs were observed, FA levels in the lipid extracts were quantified via PFB-derivatization, as described above, and no significant differences were seen in the KO cells (supplemental Fig. S4). This is not surprising, as cellular LysoPL levels are roughly 1,000-fold lower than those of FFAs; therefore, LysoPL hydrolysis is unlikely to be a major contributor to the levels of cellular FAs. Together, the data suggest that Lypla2 makes a greater contribution to LysoPL hydrolysis than Lypla1 and/or can fully compensate for the loss of Lypla1. However, the loss of both enzymes appears to unmask a role for Lypla1 that is not revealed by the single-KO cells.

Interestingly, although lipids in each of the LysoPL classes exhibited significant increases in the DKO cells, albeit at varying magnitudes, there was no consistent pattern in the exact species (as designated by the acyl chain) most affected. This suggests that LYPLA substate specificity is more dependent on LysoPL class than acyl chain identity, with LPC, LPE, and LPI species in the DKO cells increasing by >300% on average compared with WT cells. Furthermore, in contrast to in vitro studies where LYPLA2 has been shown to prefer fully saturated LysoPL substrates, unsaturated LysoPLs of each class in the DKO cells are significantly increased, especially in the LPC, LPE, and LPI classes (41). Indeed, the highest fold changes between DKO and WT cells occurred in the polyunsaturated LPCs, although these were mostly minor species. Of course, it is possible that neither Lypla1 nor Lypla2 plays a direct role in changing some LysoPL levels. It is possible that genetic deletions of multiple lipases involved in the Lands cycle alter lipid-remodeling pathways, leading to indirect increases of specific LysoPL species that may not necessarily be directly hydrolyzed by either enzyme. Such remodeling might also occur through the compensatory overexpression of other enzymes in response to the deletion. Nevertheless, these data demonstrate that the in vivo impact of a specific serine hydrolase cannot be easily predicted by in vitro studies of its substrate selectivity, stressing the importance of cellular models in studying enzymatic activity.
LysoPL signaling pathways are overactive in DKO cells

The above data indicated that **Lypla** KO leads to increases in LysoPLs, which are well-characterized signaling molecules. As activation of the MAPK pathway is commonly associated with LysoPL signaling, we evaluated the phosphorylation states of individual kinases within the MAPK cascade using LC/MS/MS.
phospho-specific Abs and compared them between WT and Lypla KO cells. When normalized to total MEK1/2, phosphorylated MEK1/2 was significantly higher in DKO than WT or either single-KO cell lines (Fig. 6A). Additionally, when normalized to total ERK1/2, phosphorylated ERK1/2 demonstrated this same trend with significant increases observed in DKO cells (Fig. 6B). The increased phosphorylation states of these proteins suggest that the elevated LysoPLs in DKO cells are activating the MAPK signaling pathway.

**Neuronal differentiation is increased in LYPLA KO cells**

The consequences of ERK phosphorylation have been extensively studied and are dependent on cell type. In neuroblastoma cells, the MAPK signaling pathway is known to induce neuronal differentiation, increasing neurite outgrowth and cell area and initiating gap junction intracellular communication (16–19). To assess the impact of MAPK signaling pathway activation in the context of LYPLA deficiency, we utilized immunocytochemistry and high-throughput imaging to compare the morphology and degree of neuronal differentiation between the WT and Lypla KO Neuro2a cells. Retinoic acid was also used as a positive control to induce differentiation in WT cells. After fixing and permeabilizing the cells in 96-well plates, the overall shape of each cell was visualized using an Ab directed toward βIII-tubulin (green). Each cell was identified using the nuclear stain DAPI to enable cell counting and normalization between samples (Fig. 7A). Multiple 10× magnification images were “stitched together” to create one composite image for each well (one replicate), and the images were processed with MetaXpress software using the neurite outgrowth application. This technology allowed us to take large-scale images of entire cell populations in 96-well plates and quickly convert them into quantitative outputs of cell sizes and morphologies as an established method of measuring neuronal differentiation (82, 83). Parameters quantified with this application include number of cells, cell body area, straightness of processes, numbers of processes and branches, and a total outgrowth measurement incorporating the lengths of all processes and branches. These parameters were normalized first to the number of cells in each sample and then to the corresponding values of WT cells to give fold changes (Fig. 7B–D). Although the straightness of the processes of each cell line was unchanged (data not shown), both the average cell body area and the average total outgrowth of the Lypla1−/−, Lypla2−/−, and DKO cells were significantly increased compared with those of WT cells. Furthermore, the average number of processes per cell was significantly increased in the DKO cells to levels comparable to that of WT cells treated with retinoic acid. Additionally, the average total outgrowth of each LYPLA KO was comparable to that of the WT cells treated with retinoic acid.

Previous studies have shown that some LysoPLs can induce or suppress neuronal differentiation (16:0 LPC and 16:0 LPA, respectively) in Neuro2a cells (17). Both of these species are present in FBS, suggesting the possibility that the conditions used to induce differentiation in the cells (a decrease in FBS content in the culture medium from 10%
to 2%) resulted in changes in their levels that contributed to the differentiation process. We confirmed the presence of \( \sim 800 \) mM 16:0 LPC and \( \sim 30 \) nM 16:0 LPA in medium containing 2% FBS, suggesting starting concentrations of \( \sim 4 \) \( \mu \)M 16:0 LPC and \( \sim 150 \) nM 16:0 LPA in medium containing 10% FBS. To directly assess the effects of these lipids on Neuro2a differentiation, we conducted experiments in which each lipid was added to differentiation medium (containing 2% FBS) at a concentration of 1 \( \mu \)M. The cells were not viable in the absence of serum, precluding carrying out these experiments under serum-free conditions. As shown in supplemental Fig. S5, the addition of 16:0 LPC significantly increased neuronal differentiation in each cell line, whereas the addition of 16:0 LPA had only modest effects on the average number of processes in DKO cells. These data suggest that the relatively low concentrations of LysoPLs in the 2% FBS-containing medium may be an external source of LYPLA substrates that mediate neuronal differentiation. However, the fact that concentrations of these lipids are actually decreased when the serum concentration is reduced to induce differentiation under our conditions suggests that they are unlikely to be playing a major role in the phenomena that we observe. Thus, it is most likely that higher levels of basal neuronal differentiation observed in DKO cells, which is comparable to those of WT cells treated with a differentiation agent, are due to increased endogenous LysoPL levels.

To further verify that the increased levels of neuronal differentiation were due to increased MAPK activation, WT and DKO cells were treated with a MEK inhibitor, PD98059, and neurite outgrowth parameters were quantified (Fig. 8). Although outgrowth parameters in cells treated with the DMSO vehicle were consistent with basal neuronal differentiation in each cell line (Fig. 7), the cell body area, number of processes, and total outgrowth of DKO cells treated with PD98059 were all significantly reduced. Furthermore, the average number of processes and total outgrowth of PD98059-treated DKO cells was comparable to that of untreated WT cells (Fig. 8C, D). These data suggest that inhibiting MAPK activation with a MEK antagonist in DKO cells counteracts the effects of increased LysoPLs on neuronal differentiation. The phenotypic changes to neuritogenesis, especially the increased total outgrowth of DKO cells, are likely due to the increased LysoPL levels and their role in the activation of the MAPK signaling cascade. If this is the case, LYPLAs are demonstrably important in maintaining LysoPL homeostasis and modulating their effects on signaling processes in cells.

**DISCUSSION**

LysoPL metabolism is a significant component of the Lands cycle, modulating the levels of potent bioactive signaling molecules and preventing membrane disruption.
(39, 42). LYPLA1 and LYPLA2 are responsible for a substantial fraction of this activity and, consequently, for regulating the signaling effects of their respective LysoPL substrates (32). Although past work has suggested that LYPLA1 and LYPLA2 display relative substrate specificity in terms of LysoPL hydrolysis, these studies have been done using recombinant enzyme and fail to accurately portray the roles of LYPALs in cellular settings. To compare the activities of these two enzymes, we have taken a multifaceted approach using in vitro and cellular assays to determine how LYPALs maintain LysoPL homeostasis.

As depicted in their crystal structures, LYPLA1 and LYPLA2 are nearly identically folded and share highly similar active sites (Fig. 2B). Accordingly, the activity of the recombinant enzymes toward the most prevalent LysoPL substrate, 16:0-LPC, is comparable (Fig. 3B). This was tested using an isotopically labeled LysoPL species, 16:0-d_{3} LPC, in order to avoid contamination by the FA products of LysoPL hydrolysis. This method allows for LC/MS/MS-based quantitation of LysoPL hydrolysis without relying on expensive radiolabeled lipid substrates or purification steps that reduce sensitivity. However, to determine whether the activity of LYPLA1 and LYPLA2 toward other LysoPLs is analogous in a setting where all substrates would be available, we developed cellular models to compare their activity.

We have characterized the roles of LYPLA1 and LYPLA2 in LysoPL hydrolysis in a neuroblastoma cell model in which Lypla1, Lypla2, or both genes were deleted. The results demonstrated minimal effects of Lypla1 deletion on LysoPL levels, although it is interesting to note that the only LysoPL species that increased in Lypla1−/− cells contained 20:4, suggesting that LYPLA1, specifically, may play a role in regulating arachidonate levels and eicosanoid biosynthesis. In contrast, Lypla2 deletion affected a greater number and broader diversity of lipid species than Lypla1 deletion, and substantial LysoPL elevation occurred only with KO of both enzymes (Fig. 5). In general, the data suggest that the two enzymes act cooperatively, with apparent compensation of one isoform for the loss of the other, although that occurs without substantial changes in protein expression (Fig. 4A). The consistent levels of protein expression in the KO cells suggest that the enzymes are constitutively expressed to modulate LysoPL levels. However, it is possible that the enzymes could undergo activation via posttranslational modification; both LYPLA1 and LYPLA2 are palmitoylated in cells at conserved Cys2, LYPLA1 is acetylated at Lys224, and LYPLA2 is phosphorylated at Ser82 (57, 84, 85). Nevertheless, it appears that LYPLA1 and LYPLA2 are able to hydrolyze the majority of LysoPLs in cells despite the differential preferences for LysoPL classes observed in vitro. One must interpret these data with caution, however, as lysates from KO cells retained substantial hydrolytic activity (Fig. 4B). The specific nature of this activity is not known, but it almost certainly has an impact on the ultimate pattern of LysoPL changes observed in the various cell lines that we explored.

In neuroblastoma cells lacking both Lypla1 and Lypla2, lysophospholipase activity is sufficiently compromised to lead to increased LysoPL levels (Fig. 5) and increased activation of the MAPK signaling pathway (Fig. 6). Correspondingly, these data suggest that LYPLA1 and LYPLA2 are able to modulate cell differentiation and neuritogenesis in neuroblastoma cells through their hydrolytic metabolism of LysoPLs (Fig. 7). The role of lysophospholipase-dependent modulation of LysoPL levels in physiological models of neurodifferentiation will be an interesting subject for further study.

In summary, we have closely compared the structures and activities of LYPLA1 and LYPLA2 and determined that the two proteins have significant overlap in their cellular functions. Both enzymes cooperate to maintain lipid homeostasis in cells; however, losing the activity of only one of these enzymes seems to have modest to no effect on LysoPL levels, suggesting that the counterpart lysophospholipase is able to compensate for that loss. However, when both enzymes are knocked out, the cells are unable to regulate levels of LysoPLs, leading to aberrant LysoPL-dependent signaling, an unregulated Lands cycle, and

---

**Fig. 8.** PD98059 inhibition of MAPK activation reduces impact of Lypla KO on neuronal differentiation. Data were quantified from images taken of 96-well plates (n = 8). A: Legend of each cohort, WT cells (white) and DKO cells (black), treated with DMSO vehicle or 10 µM PD98059. B: Average cell area normalized to vehicle-treated WT values and represented as fold changes. C: Average number of processes per cell normalized to vehicle-treated WT values and represented as fold changes. D: Average total outgrowth of cells normalized to vehicle-treated WT values and represented as fold changes. *P < 0.05, **P < 0.001; ***P < 0.0001.
Flow Cytometry experiments were performed in the VMC Flow Cytometry Shared Resource. The VMC Flow Cytometry Shared Resource is supported by the Vanderbilt Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). Antibodies were generated and purified by the Vanderbilt Antibody and Protein Resource. The Vanderbilt Antibody and Protein Resource is supported by the Vanderbilt Institute of Chemical Biology and the Vanderbilt Ingram Cancer Center (P30 CA68485). Imaging experiments were performed in the Vanderbilt High-Throughput Screening Core Facility with assistance provided by Debbie Mi and Joshua Bauer. The HTS core receives support from the Vanderbilt Institute of Chemical Biology and the Vanderbilt-Ingram Cancer Center (P30 CA68485). Statistical analyses were performed with guidance by Yu Shyr, Ph.D. from the Department of Biostatistics at Vanderbilt University.

**REFERENCES**

1. Makide, K., H. Kitamura, Y. Sato, M. Okutani, and J. Aoki. 2009. Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol. *Prostaglandins Other Lipid Mediat.* **89**:139–159.

2. Brown, W. J., K. Chambers, and A. Doody. 2003. Phospholipase A2 activity in a cellular setting and gives a clear answer to why inhibiting only LYPLA1 or LYPLA2 seems to have little to no effect (52, 86). We have focused here on the role of these proteins in maintaining LysoPL homeostasis, but their redundancy in substrate specificity may also apply to their other major function, namely, the thioesterase activity that results in the depalmitoylation of protein substrates (87). Although relatively few palmitoylated proteins have been identified as specific substrates for either LYPLA1 and LYPLA2 with palmostatin B is often required to affect global protein palmitoylation (51, 52, 86). These LYPLA1 and LYPLA2 with palmostatin B is often required to affect global protein palmitoylation (51, 52, 86). These trends are consistent with our findings that LYPLA1 and LYPLA2 share LysoPL substrates in cells and offer a clear answer to why inhibiting only LYPLA1 or LYPLA2 seems to have little to no effect (52, 86).

3. Lan, L., H. W. Podolak, K. Kolahi, L. Cheng, S. Rao, D. Garg, C. H. Xue, J. K. Rantala, J. W. Tyner, K. L. Thornburg, et al. 2017. Metabolic reprogramming enables cancer cell survival despite oncogenic signaling blockade. *Genes Dev.* **31**:2067–2084.

4. Li, P. L., and E. Gulbins. Bioactive lipids and redox signaling: molecular mechanism and disease pathogenesis. *Antioxid. Redox Signal.* Epub ahead of print, January 24, 2018.

5. Tang, X., X. Wang, Y. Y. Zhao, J. M. Curtis, and D. N. Brindley. 2017. Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-kappaB activation. *Mol. Cancer.* **16**:36.

6. Quan, H., Y. H. Hur, C. Jin, J. M. Kim, J. I. Choi, M. Y. Kim, and H. B. Bae. 2016. Stearoyl lysophosphatidylcholine enhances the phagocytic ability of macrophages through the AMP-activated protein kinase/p38 mitogen activated protein kinase pathway. *Int. Immunopharmacol.* **39**:328–334.

7. Barnes, M. J., and J. G. Cyster. 2018. Lysophosphatidylserine suppression of T-cell activation via GPR174 requires Galphas proteins. *Immuno. Cell Biol.* **96**:439–445.

8. Lorenssen, S., and M. G. Blennerhassett. 1998. Lysophosphatidylserine potentiates nerve growth factor-induced differentiation of PC12 cells. *Neuroci. Lett.* **248**:77–80.

9. Chen, H., A. Argaw, B. Cecyre, A. Bouchard, J. Gagnard, P. Javadi, S. Desgent, K. Mackie, and J. F. Bouchard. 2013. Role of GPR55 during axon growth and target innervation. *eNeuro.* **2**:ENEURO.0011-15.2013.

10. Paoletti, L., P. Domizzi, H. Marchetti, A. Montaner, D. Krapf, G. Salvador, and C. Banchio. 2016. Lysophosphatidylcholine drives neuroblast cell fate. *Mol. Neuro. Biol.* **53**:6310–6331.

11. Nishina, A., H. Kimura, A. Sekiguchi, R. H. Fukumoto, S. Nakajima, and S. Furukawa. 2006. Lysophosphatidylethanolamine in Grifola frondosa as a neurotrophic factor via activation of MAPK. *J. Lipid Res.* **47**:1434–1443.

12. Callihan, P., M. W. Ali, H. Salazar, N. Quach, X. Wu, S. L. Stice, and S. B. Hooks. 2014. Convergent regulation of neuronal differentiation and Erk and Akt kinases in human neural progenitor cells by lysophosphatidic acid, sphingosine 1-phosphate, and LIF: specific roles for the LPA1 receptor. *ASN Neuro.* **6**:1759091414558416.

13. Ikeno, Y., N. Konno, S. H. Cheon, A. Bolchi, S. Ottonello, K. Kitamoto, and M. Arioka. 2005. Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. *J. Biol. Chem.* **280**:28044–28052.

14. Khan, S. M., N. J. McLaughlin, M. R. Kelher, P. Eckels, F. Gamboni-Robertson, A. Banerjee, and C. C. Silliman. 2010. Lysophosphatidylcholine activates G2A and G1A receptors and controls neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. *J. Biol. Chem.* **280**:28044–28052.
27. Anavi-Goffer, S., G. Baillie, A. J. Irving, J. Gertsch, I. R. Greig, R. G. Pertwee, and R. A. Ross. 2012. Modulation of L-alpha-lipoylphosphatidinolinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem. 287: 91–104.

28. Zhang, W., and H. T. Liu. 2002. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12: 9–18.

29. Meloche, S., and J. Poussegur. 2007. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 26: 3272–3293.

30. Ge, C., G. Xiao, D. Jiang, and R. T. Franceschi. 2007. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176: 709–718.

31. Kanai, A., J. J. Vasko, M. Thurgau, F. E. Fontenot, M. S. Saha-El-Dein, M. Mailet, A. J. York, J. N. Lorenz, W. H. Zimmermann, S. Meloche, et al. 2011. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ. Res. 108: 176–183.

32. Wang, A., and E. A. Dennis. 1999. Mammalian lysophospholipases. Biochim. Biophys. Acta. 1439: 1–16.

33. Gross, R. W., and B. E. Sobel. 1983. Rabbit myocardial cytosolic phospholipase A. Methods Enzymol. 108: 1839–1848.

34. Zhang, Y., Y. A. Deems, and E. A. Dennis. 1991. Lysophospholipase I and II from P388D1 macrophase-like cell line. Methods Enzymol. 197: 456–468.

35. Zhang, Y. Y., and E. A. Dennis. 1988. Purification and characterization of a lysophospholipase from human amnionic membrane. J. Biol. Chem. 259: 15188–15195.

36. Lepage, N., and K. D. Roberts. 1995. Purification of lysophospholipase of human spermatozoa and its implication in the acrosome reaction. Biol. Reprod. 52: 616–624.

37. Ross, B. M., and S. J. Kish. 1994. Characterization of lysophospholipid metabolizing enzymes in human brain. J. Neurochem. 63: 1859–1868.

38. Zhang, Y. Y., and E. A. Dennis. 1991. Lysophospholipase I and II from P388D1 macrophase-like cell line. Methods Enzymol. 197: 456–468.

39. Jarvis, A. A., C. Cain, and E. A. Dennis. 1984. Purification and characterization of a lysophospholipase from human amnionic membrane. J. Biol. Chem. 259: 15188–15195.

40. Ge, C., G. Xiao, D. Jiang, and R. T. Franceschi. 2007. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176: 709–718.

41. Manna, J. D., J. A. Wepy, K. Hsu, J. W. Chang, B. F. Cravatt, and L. J. Marnett. 2011. Global profiling of dynamic protein palmitoylation. Nat. Methods. 9: 84–89.

42. Yamashita, A., T. Sugiura, and K. Waku. 1997. Acyltransferases and acyltransferase inhibitors. Biochim. Biophys. Acta. 1322: 1–16.

43. Aicart-Ramos, C., R. A. Valero, and I. Rodriguez-Crespo. 2011. Recent progress on acyl CoA: lysophospholipid acyltransferase inhibitors as probes of dynamic S-palmitoylation. MedChemComm. 2: 84–89.

44. Siess, W., K. J. Zangl, M. Essler, M. Bauer, R. Brandl, C. Corrinth, M. Camarillo, J. A. Wepy, P. S. Harris, K. S. Fritz, and L. J. Marnett. 2014. Separation and quantification of lysophosphatidic acids in rat brain tissue by liquid chromatography-negative chemical ionization gas chromatography–mass spectrometry. Anal. Chem. 87: 3843–3850.

45. Wood, P. L. 2012. Lipidomics of Alzheimer’s disease: current status. J. MedChem. 55: 8221–8226.

46. Anghileri, E., S. Marconi, A. Pignatelli, P. Cifelli, M. Galie, A. Scardi, G. Saigusa, Y. Tomioka, and J. Aoki. 2014. Separation and quantification of 2-acetyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MS. J. Lipid Res. 55: 2178–2192.

47. Aaltonen, N., J. T. Laitinen, and M. Lehtonen. 2010. Quantification of lysophosphatidic acids in rat brain tissue by liquid chromatography–mass spectrometry. Anal. Chem. 82: 999–1007.

48. Palmer, T. D., J. Takahashi, and F. H. Gage. 1997. The adult rat hippocampus contains primordial neural stem cells. Neurosci. Lett. 258: 6–10.

49. Zeng, M., and J. N. Zhou. 2008. Roles of autophagy and mTOR signaling in neural differentiation of mouse neuroblastoma cells. Cell. Signal. 20: 659–665.

50. Anghileri, E., S. Marconi, A. Pignatelli, P. Cifelli, M. Galie, A. Scardi, G. Saigusa, O. Belluzzi, and B. Bonetti. 2008. Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Stem Cells Dev. 17: 909–916.

51. Palmer, T. D., J. Takahashi, and F. H. Gage. 1997. The adult rat hippocampus contains primordial neural stem cells. Mol. Cell. Neurosci. 8: 389–404.
73. Kim, B., P. S. Leventhal, A. R. Saltiel, and E. L. Feldman. 1997. Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation. J. Biol. Chem. 272: 21268–21273.

74. Riboni, L., A. Prinetti, R. Bassi, A. Caminiti, and G. Tettamanti. 1995. A mediator role of ceramide in the regulation of neuroblastoma Neuro2a cell differentiation. J. Biol. Chem. 270: 26868–26875.

75. Devedjiev, Y., Z. Dauter, S. R. Kuznetsov, T. L. Jones, and Z. S. Derewenda. 2000. Crystal structure of the human acyl protein thioesterase I from a single X-ray data set to 1.5 A. Structure. 8: 1137–1146.

76. Won, S. J., D. Davda, K. J. Labby, S. Y. Hwang, R. Pricer, J. D. Majmudar, K. A. Armacost, L. A. Rodriguez, C. L. Rodriguez, F. S. Chong, et al. 2016. Molecular mechanism for isoform-selective inhibition of acyl protein thioesterases 1 and 2 (APT1 and APT2). ACS Chem. Biol. 11: 3374–3382.

77. Krissinel, E., and K. Henrick. 2004. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60: 2256–2268.

78. Yao, C. H., G. Y. Liu, K. Yang, R. W. Gross, and G. J. Patti. 2016. Inaccurate quantitation of palmitate in metabolomics and isotope tracer studies due to plastics. Metabolomics. 12: 143.

79. Chen, R. F. 1967. Removal of fatty acids from serum albumin by charcoal treatment. J. Biol. Chem. 242: 173–181.

80. Patterson, B. W., G. Zhao, N. Elias, D. H. Hachey, and S. Klein. 1999. Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J. Lipid Res. 40: 2118–2124.

81. Savinainen, J. R., E. Kansanen, T. Pantzar, D. Navia-Paldanian, T. Parkkari, M. Lehtonen, T. Laitinen, T. Nevalainen, A. Poso, A. L. Levonen, et al. 2014. Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL). Mol. Pharmacol. 86: 522–535.

82. Algarni, A. S., A. J. Hargreaves, and J. M. Dickenson. 2018. Activation of transglutaminase 2 by nerve growth factor in differentiating neuroblastoma cells: A role in cell survival and neurite outgrowth. Eur. J. Pharmacol. 820: 113–129.

83. Sindri, R. A., W. Harris, G. Arnott, J. Flaskos, C. Lloyd Mills, and A. J. Hargreaves. 2016. Chlorpyrifos- and chlorpyrifos oxon-induced neurite retraction in pre-differentiated N2a cells is associated with transient hyperphosphorylation of neurofilament heavy chain and ERK 1/2. Toxicol. Appl. Pharmacol. 308: 29–31.

84. Lundby, A., A. Secher, K. Lage, N. B. Nordsborg, A. Dmytriyev, C. Lundby, and J. V. Olsen. 2012. Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat. Commun. 3: 876.

85. Rardin, M. J., J. C. Newman, J. M. Held, M. P. Cusack, D. J. Sorensen, B. Li, B. Schilling, S. D. Mooney, C. R. Kahn, E. Verdin, et al. 2013. Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. Proc. Natl. Acad. Sci. USA. 110: 6601–6606.

86. Beck, M. W., R. S. Kathayat, C. M. Cham, E. B. Chang, and B. C. Dickinson. 2017. Michael addition-based probes for ratiometric fluorescence imaging of protein S-depalmitoylases in live cells and tissues. Chem. Sci. 8: 7588–7592.

87. Zeidman, R., C. S. Jackson, and A. I. Magee. 2009. Protein acyl thioesterases (review). Mol. Membr. Biol. 26: 32–41.